Arixa Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arixa Pharmaceuticals, Inc.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.